Intrinsic value of Rigel Pharmaceuticals - RIGL

Previous Close

$2.20

  Intrinsic Value

$0.12

stock screener

  Rating & Target

str. sell

-95%

  Value-price divergence*

-77%

Previous close

$2.20

 
Intrinsic value

$0.12

 
Up/down potential

-95%

 
Rating

str. sell

 
Value-price divergence*

-77%

*Intrinsic value change (in %) minus stock price change (in %) in the past 12 months.

We calculate the intrinsic value of RIGL stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2016), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.3

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  -31.03
  2.00
  2.30
  2.57
  2.81
  3.03
  3.23
  3.41
  3.57
  3.71
  3.84
  3.95
  4.06
  4.15
  4.24
  4.31
  4.38
  4.44
  4.50
  4.55
  4.59
  4.64
  4.67
  4.70
  4.73
  4.76
  4.78
  4.81
  4.83
  4.84
  4.86
Revenue, $m
  20
  20
  21
  21
  22
  23
  23
  24
  25
  26
  27
  28
  29
  30
  32
  33
  35
  36
  38
  39
  41
  43
  45
  47
  49
  52
  54
  57
  60
  63
  66
Variable operating expenses, $m
 
  57
  58
  60
  62
  63
  66
  68
  70
  73
  76
  79
  82
  85
  89
  93
  97
  101
  105
  110
  115
  121
  126
  132
  139
  145
  152
  159
  167
  175
  184
Fixed operating expenses, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  90
  57
  58
  60
  62
  63
  66
  68
  70
  73
  76
  79
  82
  85
  89
  93
  97
  101
  105
  110
  115
  121
  126
  132
  139
  145
  152
  159
  167
  175
  184
Operating income, $m
  -70
  -37
  -38
  -39
  -40
  -41
  -42
  -44
  -45
  -47
  -49
  -51
  -53
  -55
  -57
  -60
  -62
  -65
  -68
  -71
  -74
  -78
  -81
  -85
  -89
  -93
  -98
  -102
  -107
  -113
  -118
EBITDA, $m
  -69
  -37
  -37
  -38
  -39
  -41
  -42
  -43
  -45
  -47
  -48
  -50
  -52
  -55
  -57
  -59
  -62
  -65
  -68
  -71
  -74
  -77
  -81
  -85
  -89
  -93
  -97
  -102
  -107
  -112
  -118
Interest expense (income), $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
Earnings before tax, $m
  -69
  -37
  -37
  -38
  -40
  -41
  -42
  -44
  -45
  -47
  -49
  -51
  -53
  -55
  -57
  -60
  -63
  -65
  -68
  -71
  -75
  -78
  -82
  -86
  -90
  -94
  -99
  -104
  -109
  -114
  -120
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -69
  -37
  -37
  -38
  -40
  -41
  -42
  -44
  -45
  -47
  -49
  -51
  -53
  -55
  -57
  -60
  -63
  -65
  -68
  -71
  -75
  -78
  -82
  -86
  -90
  -94
  -99
  -104
  -109
  -114
  -120

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  75
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  78
  23
  24
  25
  25
  26
  27
  28
  29
  30
  31
  32
  34
  35
  36
  38
  40
  41
  43
  45
  47
  50
  52
  54
  57
  60
  62
  65
  69
  72
  75
Adjusted assets (=assets-cash), $m
  3
  23
  24
  25
  25
  26
  27
  28
  29
  30
  31
  32
  34
  35
  36
  38
  40
  41
  43
  45
  47
  50
  52
  54
  57
  60
  62
  65
  69
  72
  75
Revenue / Adjusted assets
  6.667
  0.870
  0.875
  0.840
  0.880
  0.885
  0.852
  0.857
  0.862
  0.867
  0.871
  0.875
  0.853
  0.857
  0.889
  0.868
  0.875
  0.878
  0.884
  0.867
  0.872
  0.860
  0.865
  0.870
  0.860
  0.867
  0.871
  0.877
  0.870
  0.875
  0.880
Average production assets, $m
  2
  2
  2
  2
  2
  2
  2
  2
  2
  2
  2
  2
  2
  2
  2
  2
  3
  3
  3
  3
  3
  3
  3
  4
  4
  4
  4
  4
  4
  5
  5
Working capital, $m
  53
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -4
  -4
  -4
  -4
  -4
  -5
  -5
  -5
  -5
  -5
  -6
  -6
  -6
  -7
Total debt, $m
  0
  -2
  -1
  -1
  0
  0
  1
  2
  3
  4
  5
  6
  7
  8
  10
  11
  13
  14
  16
  18
  20
  22
  24
  26
  28
  31
  33
  36
  39
  42
  45
Total liabilities, $m
  23
  21
  22
  22
  23
  23
  24
  25
  26
  27
  28
  29
  30
  31
  33
  34
  36
  37
  39
  41
  43
  45
  47
  49
  51
  54
  56
  59
  62
  65
  68
Total equity, $m
  55
  2
  2
  2
  3
  3
  3
  3
  3
  3
  3
  3
  3
  3
  4
  4
  4
  4
  4
  5
  5
  5
  5
  5
  6
  6
  6
  7
  7
  7
  8
Total liabilities and equity, $m
  78
  23
  24
  24
  26
  26
  27
  28
  29
  30
  31
  32
  33
  34
  37
  38
  40
  41
  43
  46
  48
  50
  52
  54
  57
  60
  62
  66
  69
  72
  76
Debt-to-equity ratio
  0.000
  -0.810
  -0.590
  -0.350
  -0.090
  0.180
  0.450
  0.730
  1.020
  1.300
  1.590
  1.870
  2.150
  2.420
  2.690
  2.950
  3.200
  3.450
  3.690
  3.920
  4.140
  4.360
  4.570
  4.760
  4.960
  5.140
  5.320
  5.490
  5.650
  5.800
  5.950
Adjusted equity ratio
  -6.667
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -69
  -37
  -37
  -38
  -40
  -41
  -42
  -44
  -45
  -47
  -49
  -51
  -53
  -55
  -57
  -60
  -63
  -65
  -68
  -71
  -75
  -78
  -82
  -86
  -90
  -94
  -99
  -104
  -109
  -114
  -120
Depreciation, amort., depletion, $m
  1
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Funds from operations, $m
  -92
  -37
  -37
  -38
  -39
  -41
  -42
  -43
  -45
  -47
  -49
  -50
  -53
  -55
  -57
  -60
  -62
  -65
  -68
  -71
  -74
  -78
  -82
  -86
  -90
  -94
  -98
  -103
  -108
  -114
  -119
Change in working capital, $m
  -16
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from operations, $m
  -76
  -37
  -37
  -38
  -39
  -41
  -42
  -43
  -45
  -47
  -48
  -50
  -52
  -55
  -57
  -59
  -62
  -65
  -68
  -71
  -74
  -78
  -81
  -85
  -89
  -94
  -98
  -103
  -108
  -113
  -119
Maintenance CAPEX, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
New CAPEX, $m
  -1
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from investing activities, $m
  25
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Free cash flow, $m
  -51
  -37
  -37
  -38
  -40
  -41
  -42
  -44
  -45
  -47
  -49
  -51
  -53
  -55
  -57
  -60
  -62
  -65
  -68
  -71
  -75
  -78
  -82
  -86
  -90
  -94
  -99
  -104
  -109
  -114
  -119
Issuance/(repayment) of debt, $m
  0
  -2
  0
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  2
  2
  2
  2
  2
  2
  2
  2
  2
  3
  3
  3
  3
  3
Issuance/(repurchase) of shares, $m
  25
  39
  38
  39
  40
  41
  42
  44
  45
  47
  49
  51
  53
  55
  58
  60
  63
  66
  69
  72
  75
  79
  82
  86
  90
  95
  99
  104
  109
  114
  120
Cash from financing (excl. dividends), $m  
  25
  37
  38
  40
  41
  42
  43
  45
  46
  48
  50
  52
  54
  56
  59
  61
  64
  68
  71
  74
  77
  81
  84
  88
  92
  97
  102
  107
  112
  117
  123
Total cash flow (excl. dividends), $m
  -26
  0
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  2
  2
  2
  2
  2
  2
  2
  2
  2
  3
  3
  3
  3
  3
  3
  3
  4
Retained Cash Flow (-), $m
  36
  -39
  -38
  -39
  -40
  -41
  -42
  -44
  -45
  -47
  -49
  -51
  -53
  -55
  -58
  -60
  -63
  -66
  -69
  -72
  -75
  -79
  -82
  -86
  -90
  -95
  -99
  -104
  -109
  -114
  -120
Prev. year cash balance distribution, $m
 
  55
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  16
  -37
  -38
  -39
  -40
  -41
  -43
  -44
  -46
  -48
  -50
  -52
  -54
  -56
  -58
  -61
  -64
  -67
  -70
  -73
  -76
  -80
  -84
  -88
  -92
  -96
  -101
  -106
  -111
  -116
Discount rate, %
 
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
 
  16
  -34
  -33
  -32
  -31
  -30
  -29
  -28
  -26
  -25
  -24
  -22
  -20
  -19
  -17
  -15
  -14
  -12
  -11
  -9
  -8
  -7
  -5
  -4
  -4
  -3
  -2
  -2
  -1
  -1
Current shareholders' claim on cash, %
  100
  50.0
  11.2
  2.5
  0.6
  0.1
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

Rigel Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel and targeted drug candidates in the therapeutic areas of immunology, oncology, and immuno-oncology. It is developing fostamatinib, an oral spleen tyrosine kinase inhibitor, which is in Phase III clinical trials for immune thrombocytopenic purpura and in Phase II clinical trials for autoimmune hemolytic anemia and IgA nephropathy; R348, an ophthalmic janus kinase/spleen tyrosine kinase inhibitor that is in Phase II clinical trials for the treatment of patients with ocular graft-versus-host disease; and two oncology product candidates in Phase I development. The company has license agreements with Aclaris Therapeutics International Limited for the development and commercialization of certain janus kinase inhibitors for the treatment of alopecia areata and other dermatological conditions; AstraZeneca AB for the development and commercialization of R256, an inhaled janus kinase inhibitor; BerGenBio AS for the development and commercialization of an oncology program; and with Daiichi Sankyo to pursue research related to a specific target from a novel class of drug targets called ligases, as well as a collaboration agreement with Bristol-Myers Squibb Company for the discovery, development, and commercialization of cancer immunotherapies. Rigel Pharmaceuticals, Inc. was founded in 1996 and is based in South San Francisco, California.

FINANCIAL RATIOS  of  Rigel Pharmaceuticals (RIGL)

Valuation Ratios
P/E Ratio -3.2
Price to Sales 10.9
Price to Book 4
Price to Tangible Book
Price to Cash Flow -2.9
Price to Free Cash Flow -2.8
Growth Rates
Sales Growth Rate -31%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 0%
Cap. Spend. - 3 Yr. Gr. Rate 0%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 0%
Total Debt to Equity 0%
Interest Coverage 0
Management Effectiveness
Return On Assets -65.7%
Ret/ On Assets - 3 Yr. Avg. -49.8%
Return On Total Capital -94.5%
Ret/ On T. Cap. - 3 Yr. Avg. -65.1%
Return On Equity -94.5%
Return On Equity - 3 Yr. Avg. -65.1%
Asset Turnover 0.2
Profitability Ratios
Gross Margin 0%
Gross Margin - 3 Yr. Avg. 0%
EBITDA Margin -340%
EBITDA Margin - 3 Yr. Avg. -541.6%
Operating Margin -350%
Oper. Margin - 3 Yr. Avg. -559.8%
Pre-Tax Margin -345%
Pre-Tax Margin - 3 Yr. Avg. -552.8%
Net Profit Margin -345%
Net Profit Margin - 3 Yr. Avg. -552.8%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

RIGL stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the RIGL stock intrinsic value calculation we used $20 million for the last fiscal year's total revenue generated by Rigel Pharmaceuticals. The default revenue input number comes from 2016 income statement of Rigel Pharmaceuticals. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our RIGL stock valuation model: a) initial revenue growth rate of 2% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for RIGL is calculated based on our internal credit rating of Rigel Pharmaceuticals, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Rigel Pharmaceuticals.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of RIGL stock the variable cost ratio is equal to 280%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for RIGL stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 3.5% for Rigel Pharmaceuticals.

Corporate tax rate of 27% is the nominal tax rate for Rigel Pharmaceuticals. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the RIGL stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for RIGL are equal to 7.5%.

Life of production assets of 10 years is the average useful life of capital assets used in Rigel Pharmaceuticals operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for RIGL is equal to -10%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $55 million for Rigel Pharmaceuticals - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 115.604 million for Rigel Pharmaceuticals is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Rigel Pharmaceuticals at the current share price and the inputted number of shares is $0.3 billion.

RELATED COMPANIES Price Int.Val. Rating
BMY Bristol-Myers 56.42 26.07  str.sell
AZN AstraZeneca AD 29.12 17.48  sell
JNJ Johnson&Johnso 132.63 94.54  sell
XNCR Xencor 19.94 7.11  str.sell
PFE Pfizer 32.67 28.58  hold
AKRX Akorn 31.98 24.23  sell

COMPANY NEWS

▶ 3 Top Biotech Stocks Under $5   [Aug-19-17 03:21PM  Motley Fool]
▶ Rigel reports 2Q loss   [Aug-01-17 10:40PM  Associated Press]
▶ Company News for June 20, 2017   [10:19AM  Zacks]
▶ Rigel Pharma Rises Following FDA Approval   [11:10AM  24/7 Wall St.]
▶ 3 Biotech Stocks I'd Buy Right Now   [May-15-17 04:31PM  Motley Fool]
▶ Rigel reports 1Q loss   [May-02-17 06:16PM  Associated Press]
▶ 5 Top Breakout Stocks to Boost Your Portfolio   [Mar-31-17 09:18AM  Zacks]
▶ 3 Beaten-Up Biotech Stocks: Are They Bargains?   [Mar-21-17 08:22AM  Motley Fool]
▶ 3 Stocks That Are Ridiculously Cheap Right Now   [Mar-20-17 04:22PM  Motley Fool]
▶ 5 Cheap Breakout Stocks for Superb Returns   [Mar-16-17 09:23AM  Zacks]
▶ 3 Cheap Healthcare Stocks You Can Buy Right Now   [Feb-24-17 12:57PM  at Motley Fool]
▶ Is Rigel Pharmaceuticals, Inc. (RIGL) Worthy of Your Portfolio?   [Dec-14-16 04:02PM  at Insider Monkey]
▶ 4 Companies That Destroyed Shareholders Last Week   [Oct-23-16 10:15AM  at 24/7 Wall St.]
▶ Rigel Tanks After Late-Stage Drug Failure (RIGL)   [Oct-21-16 09:35AM  at Investopedia]
▶ Why Rigel Pharma Is Falling   [12:35PM  at 24/7 Wall St.]
▶ 7 Key FDA Decisions and Clinical Trial Results Coming in Q4   [Oct-06-16 08:35AM  at 24/7 Wall St.]
▶ Heres Why These Stocks Are Trending Today   [Sep-15-16 10:57AM  at Insider Monkey]
Stock chart of RIGL Financial statements of RIGL
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD
Follow us on:   twitter   twitter   twitter   twitter

VALUATION THEORY       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2017. All rigths reserved.